2016


To access this material please log in or register

Register Authorize
2016/№4

Peculiarities of warfarin treatment in patients with atrial fibrillation in complicated clinical situations

Sokolova A. A., Tsarev I. L., Napalkov D. A.
State Budgetary Educational Institution of Higher Professional Education, “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bldg. 2, Moscow 119991

Keywords: atrial fibrillation, therapy, warfarin

DOI: 10.18087/rhj.2016.4.2221

The article discusses features of vitamin K antagonist (VKA) treatment in patients with atrial fibrillation (AF), impaired kidney function, and CHF after ACS and transcutaneous coronary interventions (TCIs).
  1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33 (21):2719–47.
  2. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012 Oct;33 (19):2451–96.
  3. Ruiz-Nodar JM, Marin F, Hurtado J, Valencia J, Pinar E, Pineda J et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008 Feb 26;51 (8):818–25.
  4. Karjalainen P, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA et al. Safety and efficacy of combined antiplatelet warfarin thera­py after coronary stenting. Eur Heart J. 2007 Mar;28 (6):726–32.
  5. Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40 (6):428–36.
  6. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008 Nov 11;118 (20):2029–37.
  7. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and / or undergoing coro­nary stenting: executive summary – Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010 Jun;31 (11):1311–8.
  8. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89 (1):65–74.
  9. National Kidney Foundation. K / DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39 (2 Suppl 1):S1–266.
  10. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010 Jun;159 (6):1102–7.
  11. Шишкова В. Н. Фибрилляция предсердий у пациентов с хронической болезнью почек: возможность применения антикоагулянтов. Трудный пациент. 2015;13 (7):42–7 [Shishkova V. N. Fibrillyacziya predserdij u paczientov s xronicheskoj bolezn`yu pochek: vozmozhnost` primeneniya antikoagulyantov. Trudny`j paczient. 2015;13 (7):42–7].
  12. Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP, Schurgers LJ. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012 Jul;26 (4):155–66.
  13. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011 Jul;80 (2):181–9.
  14. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009 Oct;20 (10):2223–33.
  15. Limdi NA, Lidmi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010 Nov;56 (5):823–31.
  16. Hughes S, Szeki I, Nash MJ, Thachil J. Anticoagulation in chronic kidney disease patients – the practical aspects. Clin Kidney J. 2014 Oct;7 (5):442–9.
  17. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major blee­ding and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016 Apr;149 (4):951–9.
  18. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014 Dec 16;64 (23):2471–82.
  19. Linssen GC, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011 Oct;13 (10):1111–20.
  20. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137 (2):263–72.
  21. Shantsila E, Lip GY. Preventing thrombosis to improve outcomes in heart failure patients. Prog Cardiovasc Dis. 2016 Jan-Feb;58 (4):386–92.
  22. Lee VW, You JH, Lee KK, Chau TS, Waye MM, Cheng G. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis. 2005 Aug;20 (1):33–8.
  23. Björck F, Renlund H, Svensson PJ, Själander A. Warfarin persistence among stroke patients with atrial fibrillation. Thromb Res. 2015 Oct;136 (4):744–8.
  24. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H. Use of warfarin in elderly patients with non-valvular atrial fibrillation – subanalysis of the J-RHYTHM Registry. Circ J. 2015;79 (11):2345–52.
  25. Berlowitz DR, Miller DR, Oliveria SA, Cunningham F, Gomez-Caminero A, Rothendler JA. Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. Pharmacoepidemiol Drug Saf. 2006 Nov;15 (11):799–807.
  26. Kose E, Arai S, An T, Kikkawa A, Aoyama T, Matsumoto Y, Hayashi H. Analysis of factors affecting time in therapeutic range control after warfarin administration. Pharmazie. 2015 Jul;70 (7):494–8.
  27. Tagaya M, Yoshikawa D, Sugishita Y, Yamauchi F, Ito T, Kamada T et al. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels. 2016 Jun;31 (6):957–62.
Sokolova A. A., Tsarev I. L., Napalkov D. A. Peculiarities of warfarin treatment in patients
with atrial fibrillation in complicated clinical situations. Russian Heart Journal. 2016;15 (4):260–264

To access this material please log in or register

Register Authorize
Ru En